Acadia Healthcare (NASDAQ:ACHC – Get an Assessment) had its price target raised by analysts at SVB Leerink from $95.00 to $103.00 in a research note released on Friday, reports The Fly. The company currently has an “outperform” rating on the stock. SVB Leerink’s target price would indicate a potential upside of 20.85% from the stock’s previous close.
Other analysts have also recently published research reports on the stock. Jefferies Financial Group raised its target price on Acadia Healthcare shares from $85.00 to $95.00 in a report Thursday, July 28. Mizuho raised its price target on Acadia Healthcare from $64.00 to $69.00 in a Wednesday, May 4 research report. Deutsche Bank Aktiengesellschaft raised its target price on Acadia Healthcare from $70.00 to $82.00 in a Monday, August 1 research report. UBS Group raised its price target on Acadia Healthcare from $82.00 to $90.00 and gave the company a “buy” rating in a Thursday, July 28 research note. Finally, BMO Capital Markets raised its price target on Acadia Healthcare from $67.00 to $82.00 in a Friday, May 6 research note. Two investment analysts gave the stock a hold rating and four gave the stock a buy rating. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $83.33.
Acadia Healthcare Stock up 1.4%
Shares of Acadia Healthcare opened at $85.23 on Friday. The company has a debt ratio of 0.52, a quick ratio of 1.17 and a current ratio of 1.17. Acadia Healthcare has a 52-week minimum of $50.07 and a 52-week maximum of $85.30. The stock has a market capitalization of $7.74 billion, a price/earnings ratio of 27.94, a P/E/G ratio of 1.99 and a beta of 1.30. The company’s 50-day moving average price is $76.52 and its 200-day moving average price is $69.68.
Acadia Healthcare (NASDAQ:ACHC – Get Rating) last released its quarterly results on Wednesday, July 27. The company reported earnings per share of $0.84 for the quarter, beating the consensus estimate of $0.77 by $0.07. The company posted revenue of $651.72 million for the quarter, compared to $650.80 million expected by analysts. Acadia Healthcare achieved a net margin of 11.32% and a return on equity of 10.34%. The company’s revenue for the quarter increased by 11.9% compared to the same quarter last year. In the same quarter a year earlier, the company posted earnings of $0.71 per share. Equity research analysts expect Acadia Healthcare to post EPS of 3.08 for the current year.
Insider Activity at Acadia Healthcare
Separately, director William M. Petrie sold 6,000 shares of the company in a transaction that took place on Friday, July 29. The stock was sold at an average price of $83.42, for a total transaction of $500,520.00. Following completion of the transaction, the administrator now directly owns 31,769 shares of the company, valued at approximately $2,650,169.98. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Acadia Healthcare news, Director William M. Petrie sold 6,000 shares of the company in a trade that took place Friday, July 29. The stock was sold at an average price of $83.42, for a total value of $500,520.00. Following completion of the transaction, the administrator now directly owns 31,769 shares of the company, valued at approximately $2,650,169.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, Executive Vice President John S. Hollinsworth sold 10,780 shares of the company in a transaction that took place on Thursday, August 4. The stock was sold at an average price of $80.68, for a total value of $869,730.40. Following the completion of the transaction, the executive vice president now owns 80,559 shares of the company, valued at $6,499,500.12. The disclosure of this sale can be found here. In the past ninety days, insiders have sold 29,094 shares of the company worth $2,375,868. 1.90% of the shares are held by insiders of the company.
Institutional entries and exits
Several hedge funds and other institutional investors have recently increased or reduced their stake in ACHC. Vanguard Group Inc. increased its equity stake in Acadia Healthcare by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 8,429,847 shares of the company worth $552,408,000 after acquiring an additional 69,730 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Acadia Healthcare by 0.3% in Q1. JPMorgan Chase & Co. now owns 4,026,016 shares of the company valued at $263,825,000 after purchasing an additional 12,583 shares during the period. Alliancebernstein LP increased its stake in Acadia Healthcare by 26.3% during the 4th quarter. Alliancebernstein LP now owns 2,748,073 shares of the company valued at $166,808,000 after purchasing an additional 571,384 shares during the period. State Street Corp increased its stake in Acadia Healthcare by 2.7% in the first quarter. State Street Corp now owns 2,398,622 shares of the company valued at $157,182,000 after purchasing an additional 63,650 shares during the period. Finally, Viking Global Investors LP increased its stake in Acadia Healthcare by 1.9% during the 1st quarter. Viking Global Investors LP now owns 2,130,433 shares of the company valued at $139,607,000 after purchasing an additional 39,857 shares during the period. 99.66% of the shares are currently held by institutional investors.
About Santé Acadie
(Get an evaluation)
Acadia Healthcare Company, Inc provides behavioral health services in the United States and Puerto Rico. The company provides behavioral health care services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to firstname.lastname@example.org.
Before you consider Acadia Healthcare, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Acadia Healthcare was not on the list.
Although Acadia Healthcare currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here